Clinical analysis of decitabine combine with different regimens in the treatment of elderly patients with acute myeloid leukemia
10.3760/cma.j.issn.1009-9921.2014.08.010
- VernacularTitle:地西他滨联合不同化疗方案治疗老年人急性髓系白血病的临床观察
- Author:
Kai YANG
;
Huiren CHEN
;
Xuepeng HE
;
Jixing LOU
;
Zhi GUO
;
Yuan ZHANG
;
Peng CHEN
- Publication Type:Journal Article
- Keywords:
Leukemia;
Decitabine;
IA regimen;
CAG regimen
- From:
Journal of Leukemia & Lymphoma
2014;23(8):484-487
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic effects and adverse reactions of decitabine combined with IA or CAG regimen in the treatment of elderly patients with acute myeloid leukemia.Methods A retrospective analysis was made to observe the therapeutic effects and adverse reactions of 47 elderly patients with acute myeloid leukemia,who were divided into DAC+IA group (17 cases) and DAC+CAG group (28 cases) according to the different chemotherapy.Results In DAC+IA group,the rate of complete remission was 29.4 ％ (5/17),the rate of partial remission was 35.3 ％ (6/17),the effective rate was 64.7 ％ (11/17).In DAC+CAG group,the rate of complete remission was 26.7 ％ (8/30),the rate of partial remission was 30.0 ％ (9/30),the effective rate was 56.7 ％ (17/30),the difference between the two groups was not statistically significant (x2 =0.227,P =0.716).In DAC+IA group the median remission time and the median suvival time were 4.0 and 8.1 months,respectively.And they were 4.0 and 8.1 months,respectively,in DAC+CAG group.No significant difference was showed between the two groups (P value was 0.835,0.266,respectively).Conclusions Compared with decitabine combined with CAG regimen,decitabine combined with IA regimen has similar effect and can be well tolerated.Accordingly,decitabine combined with IA regimen can be used as first-line treatment for elderly patients with acute myeloid leukemia.
